GEHC Stock Analysis — GE Healthcare
Sector: Healthcare
AI Verdict
GE Healthcare trades cheap for the growth you're getting, but the overbought RSI means any disappointment could spark a quick correction unless its hospital equipment moat delivers as expected.
Competitive Moat
GE Healthcare dominates in medical imaging and diagnostics equipment, benefiting from decades-long hospital relationships and a vast installed base that locks in recurring service and upgrade revenue. Its scale and integration across imaging, diagnostics, and digital health make it hard for smaller competitors to match its breadth or support footprint.
Summary
GE Healthcare trades at just 13.5x forward earnings while analysts expect 22.4% EPS growth, making it a rare value in medical technology.
Where It Stands
Shares are up -0.32% over the past year with an RSI of 70.0 (pullback risk), and the forward P/E of 13.5x is well below the healthcare sector median of 22x.
Key Metrics
- RSI: 70 — Near Overbought
- Trailing P/E: 16.5x
- Forward P/E: 13.5x
- PEG Ratio: 0.81
- Earnings Growth: +0.2%
- Revenue Growth: +0.1%
- Dividend Yield: 0.00%
- 1-Year Return: -0.32%
- 52-Week High: $89.77
- 52-Week Low: $58.75
Analyst Consensus
19 Buy · 9 Hold · 0 Sell (28 analysts)
Bull Case
With forward EPS growth projected at 22.4% and a forward P/E of 13.5x, you're paying a low price for above-average growth if GEHC's entrenched hospital relationships hold up.
Bear Case
The RSI at 70.0 signals overbought conditions, so even a modest P/E compression to the sector median of 22x could trigger a sharp pullback from current levels.
Catalyst to Watch
Watch for upcoming earnings or major hospital contract wins, as confirmation of double-digit EPS growth would support the current valuation.